Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

End of Year Sale!
Grab Our Small Cap Recommendation
Service at a 60% Discount




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Metal stocks lead among gainers
Mon, 12 Aug 01:30 pm

Backed by persistent buying activity, Indian equity markets continued to trade strong during the post noon trading session. Barring stocks from banking and oil and gas sectors all the indices are trading in green. Stocks from metal and healthcare sectors are among the leading gainers.

BSE-Sensex is up by 210 points and NSE-Nifty is trading up by 57 points. While BSE Mid Cap is trading up by 1.27%, BSE Small Cap index is trading up by 1.30%. The rupee is trading at 60.73 to the US dollar.

Majority of automobile stocks are trading in the green with Hero Motor Corporation and Eicher Motors leading the pack of gainers. As per the financial daily, Society of Indian automobile manufacturers (SIAM) has reported a 7.4% YoY decline in the domestic car sales for the month of July 2013. Motorcycle sales too have declined by 1.52% YoY during this period. Total sales of the commercial vehicles declined by 14.93% YoY. Total sales across all the categories too declined by 2.08% YoY. The trend indicates, that the demand for the automobile segment continues to remain weak. The sales have declined for the ninth consecutive month.

Most of the Indian pharma Stocks are trading in green, with Orchid chemicals and Aurobindo Pharma witnessing maximum buying interest. As per the financial daily, Aurobindo pharma is looking to restructure its business and thus have taken some steps in those lines. The board has approved spinoff of its injectable business to a wholly owned subsidiary as a going concern. Reportedly, this will help company to strengthen its focus in injectable business and also offer various strategic opportunities. The board also has given approval to buy additional 57% stake in the Silicon life sciences. The said company is engaged in the manufacturing of non-sterile penems. Post the acquisition of this stake, the total stake of Aurobindo will increase to 75%. The company will also buy 60% stake in a manufacturing facility (this facility is still under construction) for the cash consideration of Rs 156 m. The said facility is being established by Celon Laborator

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Metal stocks lead among gainers". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.